CASE STUDY

Vectorborne Diseases & Climate Change


 

A female in her thirties presents to an emergency room in Miami, Florida with fever, headache, and flank pain.  

This case will guide you through a clinical encounter to understand the patient's health challenges – and how to respond.

LEARNING OBJECTIVES


  • Understand how climate change can affect risks for vector-borne diseases 

  • Identify sentinel cases of vector-borne disease related to climate change 

  • Understand the role of the clinician in the diagnosis, management, and prevention of vector-borne diseases

CLINICAL COMPETENCIES


  • Integrate history of vector exposure into patient history

  • Develop a differential diagnosis for vector-borne disease 

  • Understand and prioritize diagnostic testing for vector-borne disease

  • Identify populations at increased vulnerability to vector-borne disease

  • Access and integrate surveillance data / local outbreak and entomology data to improve diagnostic accuracy 

  • Detect sentinel cases of vector borne disease

  • Integrate weather data/extreme events and local environmental factors to inform the differential diagnosis 

  • Access resources to guide clinical management of climate sensitive infections 

  • Educate patients, communities, and policy makers about prevention and the link between vector-borne disease and climate change

A Continuing Medical Education activity presented by the Stanford Center for Innovation in Global Health and the University of Washington. View CE information and claim credit HERE.

Clinical Approach

Consider the following questions as you work through this case:

Vector-borne diseases result from infections transmitted to humans and other animals by vectors including mosquitoes, ticks, and fleas.

Key steps in diagnosis of vector borne disease:

History, inquire about bites, precautions taken (e.g., use of insect repellent, bed nets), and sentinel cases nearby, human or animal. Testing for the right diseases with the right tools can allow for earlier treatment once the final diagnosis is certain.    

Understand the prevalent vectors in your area and know how to use risk maps and weather data to evaluate the risk of vector-borne diseases where you practice.

Access to data on vector risk can improve diagnosis. 

History

Taking a clinical history of your patient yields the following information:

Chief complaint

  • Nausea, vomiting, and bilateral flank pain for two days

History of present illness

  • Fever for six days. She was seen in the emergency department three days before with fever, malaise, arthralgia, diagnosed with viral syndrome, and prescribed Ibuprofen.
  • For the past two days she has had intermittent nausea, vomiting, and flank pain worse on right.

Past medical & surgical history

  • Asthma
  • Obesity (BMI 31)
  • Nephrolithiasis

Medications

  • Asthma inhaler
  • Ibuprofen recently prescribed

Allergies

  • None

Family history

  • N/A

Social & enviromental history ("Social-E")

  • Married
  • No significant alcohol, tobacco, or drugs
  • Took a two-week trip to Honduras, returned home five weeks ago. Was in an urban environment and stayed with friends
  • No more recent travel
  • Lives in Florida, in a single family home near a lake
  • Works in an office

Review of systems

  • Also reports chills, malaise, diarrhea, arthralgia, myalgia, headache, dizziness, eye pain, bone pain, dysuria

Discussion

What else would you want to know? What conditions are you already considering for your differential diagnosis?

What parts of the physical exam would you pay closer attention to?

Key Questions for Patient

Asking your patient the following questions gives you this information:

Are you immunocompromised in any way?

  • Immunocompromised individuals are more susceptible to TB, fungal, and unique opportunistic infections.
  • The patient does not believe she is immunocompromised.

When was your last menstrual period?

  • Trying to assess chance of pregnancy
  • Pregnant women are at increased risk of severe infections.
  • No recent sexual contact.

Did you come into contact with anyone with TB or other respiratory diseases? Did you have sex while you were abroad?

  • If yes to sexual activity, think about hepatitis viruses and STDs.
  • The patient did not come into contact with anyone sick.

Did you come into contact with untreated freshwater? Unpasteurized dairy or raw food? Soil?

  • Coming into contact with contaminated freshwater may lead to schistosomiasis or leptospirosis.
  • Eating unpasteurized dairy or raw food may result in Brucellosis, Q fever, or typhoid fever.
  • Indirect contact with soil increases risk of helminths.
  • The patient did not remember coming into contact with untreated freshwater, unpasteurized dairy, or raw food.

Were you bitten by an insect or other animal recently, either when traveling or at home?

  • Mosquito and tick bites are risk factor for vector-borne disease.
  • Animal bites: cellulitis, Bartonella, rabies, rat-bite fever, other
  • The patient was not bitten by an animal recently, does not recall mosquito or tick bites during the trip. However, she did recall some mosquito bites recently in Florida, while she was out on her deck, and that the mosquitoes have been worse recently.
  • She does not use bed nets or repellent either traveling or at home.

Physical Exam

When you examine your patient, you learn the following:

General

  • Appears ill
  • Temp 38.4°C (febrile), BP 88/62 mmHg (hypotensive with orthostasis), HR 119 (tachycardic), 24 breaths/min (tachypneic)

Head Eyes Ears Nose Throat (HEENT)

  • Eyes with bilateral palpebral edema with conjunctival injection
  • Throat and nose with no evidence of mucosal bleeding

Neck

  • Supple; no masses

Chest & lungs

  • Clear lungs, rapid breathing

Cardiovascular

  • Regular, rapid rhythm, no murmurs

Abdominal

  • Slightly distended, some generalized abdominal tenderness with guarding in the right upper quadrant, no rebound tenderness
  • Rectal negative for occult blood

Genitourinary

  • No costovertebral angle tenderness
  • Pelvic exam without uterine enlargement or discrete ovarian tenderness

Skin

  • No rash, no petechiae or purpura

Musculoskeletal

  • No deformities

Neurological

  • Drowsy but can answer questions
  • Cranial nerves intact, movements symmetric, strength equal
  • Gait unsteady

Discussion

What is your differential diagnosis?

Based on the clinical context, is there any additional testing you would pursue?

Diagnostics

Information that will be helpful in diagnosing your patient:

Labs: 

  • Complete blood count shows low white blood cell count (2,600 cells/u3) otherwise normal

  • Metabolic panel, serum lactate, coagulation studies, and urinalysis normal 

  • Malaria parasite smear negative

  • Influenza RT-PCR negative

  • Chest x-ray normal

  • Ultrasound: Cholelithiasis, echogenic liver, normal common bile duct diameter 

  • Abdominal CT scan: Gallbladder distension and wall thickening with pericholecystic fluid

Repeat labs hospital day 1:  

  • New thrombocytopenia (platelets 62,000)

  • White blood cell count 15,000 cells/uL

  • Aspartate aminotransferase [AST] 265 units/L (normal: 15–46)

  • Alanine aminotransferase [ALT] = 100 units/L (normal: 9–52)

  • Alkaline phosphatase [ALP] = 164 units/L (normal: 38–126)

Key Points: Diagnostics

CONSIDER THE FOLLOWING INFORMATION:

  • Tourniquet test: Inflate BP cuff between systolic and diastolic for 5 min, observe 10 or more petechiae per 2.5 cm (1 inch) square

  • CBC with differential:

    • Leukopenia – viral infection (ie. HIV, Dengue), Typhoid

    • Thrombocytopenia – malaria, Dengue, HIV, typhoid, sepsis/DIC

  • CMP: Pay attention to elevated LFTs

  • Blood cultures: Two sets prior to antibiotics

  • Thick and thin blood smears; rapid diagnostic testing for Malaria: Three thick films/RDTs over 72 hours to exclude malaria with confidence 

  • UA with urine culture: Proteinuria and hematuria in leptospirosis

  • Nucleic acid amplification testing (NAAT), serology, antigen test:

    • Acute and convalescent serum (SLOW turnaround, limited specificity)

    • NS1 antigen test for dengue – first seven days of illness

    • PCR – first 5 days of illness

    • Whole genome sequencing – can determine source

Differential Diagnosis

For altered mental status, fever, and respiratory distress, here are some etiologies you should consider:

Fever suggests infectious cause, but consider non-infectious intra-abdominal process as well. 

  • Broad differential, including: 

    • Urinary tract infection, pyelonephritis

    • Appendicitis, other intra-abdominal processes such as cholecystitis

    • Gastroenteritis

    • Viral illnesses (myalgia, arthralgia suggests viral) 

    • Consider pregnancy/ectopic/pelvic infection

  • For history: Think vulnerability, geography & timing

    • Vulnerability: Immunocompromised? Pregnant?

    • Geography: For Florida and the Caribbean, influenza is common, and consider whether there are regional outbreaks of malaria, dengue, and Chikungunya. Recent data on infection incidence and vector abundance in your area are important!

    • Timing: Most pathogens (eg. arboviruses, hemorrhagic fever viruses, respiratory viruses, Rickettsiae) have an incubation period of < 21 days. Some, such as TB, malaria, protozoal, and HIV, have longer periods. Therefore, many travel-related infections would have presented earlier.

  • The myalgia and arthralgia and thrombocytopenia suggest arboviral illnesses – what are some to consider? 

  • Some arboviral illnesses: Dengue, Zika, Chikungunya – some important similarities and differences.

  • Given the severe clinical picture (shock, thrombocytopenia), consider dengue!

*Islands of white within red maculopapular rash is pathognomonic for dengue

(Note: not all dengue patients have a rash!)

Final Diagnosis

the patient’s story continues – leaving you with a final diagnosis:

Dengue PCR positive, dengue antibody testing for IgG and IgM: dengue confirmed 

  • In this case, travel to Honduras was too long ago for arbovirus infection acquired there, so this suggests local transmission. 

  • Hemorrhagic presentation suggests dengue (but consider other causes of hemorrhagic fever, depending on geography: Lassa, Marburg, Ebola, Rift Valley Fever, Leptospirosis).

  • Shock, bleeding, organ failure indicates severe dengue (usually associated with reinfection).

Discussion

How do we treat dengue virus?

  • For viral diseases, including hemorrhagic fever, supportive care is critical mainstay.

  • Antivirals under development for arbovirus infections but are not in use. 

  • For bacterial and parasitic diseases: Treat specific cause.

Management & Treatment

You can help your patient in the following ways:

Reducing host vulnerability / susceptibility (host factors):

  • Optimize host status / treat immunocompromised conditions

Reducing exposures / improving environments (environmental factors):

  • Be aware of high-risk areas and take extra precaution!

  • Avoid vector-prone habitat (marshy areas, high grass, etc.)

  • Personal protective equipment/clothing: Permethrin-impregnated clothing

  • Use of repellents:

    • DEET

    • Picaridin (known as KBR 3023 and icaridin outside the US)

Prevention

How can dengue virus infection be prevented?

*Customize use of the insect repellent that’s right for an individual

Beyond the Clinic

Your patient's story is part of a bigger picture:

Climate change will also increase the burden of vector-borne disease. Due to changing environmental conditions and increasing average temperatures more hospitable to mosquitoes, dengue may be locally spread in eastern North America and southern Europe, and West Nile virus is predicted to be much more prevalent in all parts of the US by the end of this century. Warmer spring temperatures due to climate change may prompt an earlier start to mosquito activity and therefore lead to a longer virus amplification period for West Nile.

Aedes spp. mosquitoes (including Aedes aegypti and A. albopictus) are the vectors for a number of arboviruses, including dengue, Zika, Chikungunya, and yellow fever. Aedes mosquitoes are extending their range on several continents as a result of climate change. Zika virus and Chikungunya were previously unheard of in the United States but are now spreading locally as more species of mosquitoes, previously only found in the tropics, move northward. Urbanization, increased global trade, and increased global travel have further promoted the worldwide spread of vectors such as Aedes spp. Overall, disease-carrying mosquitoes will reach an additional 500 million people by 2050, including 55 million more Americans.

In addition to mosquitoes, other vectors, such as ticks, are prevalent in North America. Tick-borne diseases are becoming more prevalent as ticks expand their range, given the warming climate and milder winters. Ticks can spread infectious diseases like Lyme disease, babesiosis, anaplasmosis, and rickettsial disease, and they may also trigger alpha-gal allergy. Furthermore, Chagas disease, spread by the triatomine bug, and leishmaniasis, spread by sand flies, are also expanding their range in North America. 

Given the potential devastating impacts of new vector-borne diseases in unprepared populations, it’s critical that “sentinel cases” be detected. Sentinel cases are events that indicate a changing disease risk – the “canary in the coal mine” or “tip of the iceberg” of an incoming onslaught of new vector-borne disease. For instance, birds are the natural reservoir for West Nile virus and are relatively unaffected by it; it has been shown that birds first carried West Nile from coast to coast in the United States in 1999. The first few cases can be in either humans or animals before ultimately spreading between humans, making communication between veterinarians and clinicians in human medicine even more important.

Source: CDC Vital Signs, May, 2018

Case Follow Up

What happens next:

  • The patient was hospitalized, given broad spectrum antibiotics and IV fluid boluses for suspicion of acute cholecystitis and sepsis. 

  • On day 2 of entering the hospital, laparoscopic cholecystectomy performed; findings of gallbladder inflammation, diffuse bleeding from gallbladder fossa. 

  • Day 3, the patient develops shock, abdominal distension, and lactic acidosis. Repeat surgery, complicated by Acute Respiratory Distress Syndrome (ARDS) and multi-organ failure. The patient receives empiric doxycycline for leptospira and rickettsia. 

  • Day 4, the hospital sends blood studies for malaria, dengue, and Chikungunya. 

  • After multiple transfusions and two additional surgeries for drainage, patient develops fungemia and cerebral edema and dies on day 29. 

  • RNA sequencing of dengue virus in samples from patient showed dengue serotype 2: relationship to strain first seen in Cuba, now circulating in Miami: indicating that it was locally acquired in the United States.

  • After this “sentinel case,” several hundred additional imported cases were detected, including 19 locally acquired cases. This was evidence for spread of the vector risk. 

  • Statewide clinician awareness education took place about avoiding the use of ibuprofen in suspected cases of dengue (to avoid bleeding), as well as dengue diagnosis and the need to report cases. 

  • Hospital protocols were changed to automate molecular testing (PCR) for suspected dengue cases.

  • Public health conducted educational outreach in communities and airports about prevention of mosquito bites, recognition of febrile syndromes, and free testing for dengue and other arbovirus infection. 

Discussion

What made the clinicians suspect vector-borne disease in the hospital after the first surgery on day 4?  

How could clinicians have suspected and diagnosed dengue earlier?

Call to Action

Clinicians can take action to advance planetary health:

At the clinic: 

  • Educate patients about vector-borne disease and prevention

  • Ensure clinicians have access to up to date vector risk maps and data

  • Ensure clinic has access to weather data that can affect vector risk

  • Report cases to health department or other relevant agencies

In your community: 

  • Educate patients, communities, and policymakers about the role of climate change in vector-borne disease risk through meetings, social media, and op-eds

  • Communicate with veterinarians about sentinel cases of vector-borne disease and weather related outbreaks in humans and animals

At the societal level:

  • Raise awareness of the changing threat of vector-borne disease 

  • Advocate for climate change mitigation measures at the local, state, and federal levels by voting and calling, emailing, and/or meeting with your representatives   

Summary &
Key Learning Points

also available for download here:

Approach to diagnosis of vector-borne disease:

  • Key points in history and physical (eg. travel to endemic areas, history of any bites, history of precautions taken, history of sentinel cases nearby)

  • Understand biology of vectors

  • Use of risk maps and alerts – know what vector-borne diseases are occurring in your area!

  • Use of weather data – weather events can increase risk of vector-borne disease.

  • Sentinel cases – in humans and (when relevant) in animals – are an indicator of risk!

  • Appropriate diagnostics

  • Serology is less helpful in an acute care setting; instead molecular diagnostics (eg. Nucleic Acid Amplification Tests/NAATs) and rapid antigen tests are needed.

Management & treatment of vector-borne disease:

  • For viral diseases, supportive care is critical

  • Antivirals under development

  • Bacterial and parasitic diseases: Treat specific cause

Prevention:

Reducing host vulnerability / susceptibility (host factors)

  •  Optimize host status / treat immunocompromised conditions

Reducing exposures / improving environments (environmental factors)

  • Be aware of high risk areas (maps, data, etc.) and educate patients in risk areas to take extra precaution!

  • Avoid vector-prone habitat (marshy areas, high grass, etc.)

  • Personal protective equipment/clothing: Permethrin-impregnated clothing

  • Use of repellents: DEET/ Picaridin, others

Additional Resources

Maps 

Datasets 

Articles for further reading

Further Learning

References


Ebi KL, Nealon J. Dengue in a changing climate. Environmental Research. 2016;151:115-123. doi:10.1016/j.envres.2016.07.026

Dostal T, Meisner J, Munayco C, García PJ, Cárcamo C, Pérez Lu JE, Morin C, Frisbie L, Rabinowitz PM. The effect of weather and climate on dengue outbreak risk in Peru, 2000-2018: A time-series analysis. PLoS Negl Trop Dis. 2022 Jun 30;16(6). 

Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, Moore CG, Carvalho RG, Coelho GE, Van Bortel W, Hendrickx G, Schaffner F, Elyazar IR, Teng HJ, Brady OJ, Messina JP, Pigott DM, Scott TW, Smith DL, Wint GR, Golding N, Hay SI. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife. 2015 Jun 30;4:e08347.

Kraemer MUG, Reiner RC, Brady OJ, et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol. 2019;4(5):854-863. doi:10.1038/s41564-019-0376-y 

Reich S. What’s the Buzz? Birds, Horses, People Get West Nile Virus. University of Illinois College of Veterinary Medicine. Published July 24, 2018. https://vetmed.illinois.edu/pet-health-columns/birds-horses-people-west-nile-virus/

Ryan SJ, Carlson CJ, Mordecai EA, Johnson LR. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. Han BA, ed. PLoS Negl Trop Dis. 2019;13(3):e0007213. doi:10.1371/journal.pntd.0007213

Sharp TM, Morris S, Morrison A, de Lima Corvino D, Santiago GA, Shieh WJ, Rico E, Kopp E, Muñoz-Jordán JL, Marttos A, Paz-Bailey G, Abbo LM, Stanek D; 2019 Florida Dengue Investigation Team. Fatal Dengue Acquired in Florida. N Engl J Med. 2021 Jun 10;384(23):2257-2259.

Stephenson C, Coker E, Wisely S, Liang S, Dinglasan RR, Lednicky JA. Imported Dengue Case Numbers and Local Climatic Patterns Are Associated with Dengue Virus Transmission in Florida, USA. Insects. 2022 Feb 3;13(2):163.

Read More